Propanc Health Group Corporation — Form 10-Q Summary
Period and entity: The filing covers the quarter and nine months ended March 31, 2013, for Propanc Health Group Corporation and its Australian subsidiary. This corresponds to fiscal 2013 Q3, not calendar 2012 Q3. The filing’s registrant name also differs from the requested company name, Propanc Biopharma, Inc.; confirm the entity and period before relying on this summary. Financial statements are unaudited.
Business context and financial results
The company describes itself as a development-stage cancer-treatment research company. It had no products available to market, no products in clinical trials, and no revenue in either the three- or nine-month periods ended March 31, 2013. The statements report $30,974 of royalty revenue from inception, but none during the current or comparative periods.
| Metric | Three months ended March 31, 2013 | Nine months ended March 31, 2013 | Prior-year comparable |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating expenses | $229,367 | $1,172,127 | $3,094,699 and $9,045,343, respectively |
| Net loss | $337,672 | $1,217,990 | $3,096,178 and $8,875,611, respectively |
| Research and development expense | Not separately stated for the quarter | $1,744 | $5,317 for nine months |
| Net cash used in operating activities | Not provided for the quarter | $96,701 | $114,321 for nine months |
The nine-month 2013 net loss includes a $107,939 loss on settlement. The company reported an income tax benefit of $61,150 for the nine-month period, attributed to Australian research and development tax credits. Basic and diluted loss per share was reported as $0.02 for the nine months; the three-month amount was shown as a dash. No gross profit was reported because there was no revenue.
Liquidity, debt and capital
- At March 31, 2013, cash was $0, the bank overdraft was $101, and current assets were $423. Current liabilities were $751,974, producing a reported working-capital deficit of $751,551.
- Total assets were $4,138, compared with $46,268 at June 30, 2012. Stockholders’ deficit was $747,836, versus $537,919 at June 30, 2012.
- Nine-month financing cash inflows were $98,992. The company used $96,701 in operating cash and had no investing cash flows; cash declined by $179 to zero.
- Current liabilities included $210,576 of accounts payable, $247,332 of accrued expenses and other payables, $65,278 due to directors, $140,359 in director loans, and $37,498 in other loans. The filing identifies certain director and stockholder loans as in default.
- A $75,000 convertible debenture was converted into shares in September 2012. The filing reports 70,632,268 common shares outstanding at March 31, 2013 and as of May 20, 2013.
Material changes, outlook and risks
- Operating expenses and net losses were substantially lower than in the prior-year periods. Management attributes the reductions mainly to lower amortization of prepaid stock issued for services in 2013; this does not indicate revenue growth.
- Management estimated that approximately $7.5 million would be needed to fund operations and the development program over the next 12–18 months. It stated that available cash was insufficient to fund the next twelve months, while also stating that existing cash would fund operating activities only until June 2013. The filing says the company was pursuing additional capital through registered securities.
- The filing raises substantial doubt about the company’s ability to continue as a going concern, citing no revenue, losses, minimal cash, a working-capital deficit, loan defaults, and accumulated development-stage losses of $16,498,705. Continued operations depend on financing, development progress, patent outcomes, and eventual sales; no assurance is given.
- Development work included preclinical activities for the lead product and research into its mechanism of action. The company reported that its international patent application had entered national-phase filings in multiple jurisdictions and that a patent had been granted in South Africa.
- Disclosure controls and procedures were deemed ineffective due to a material weakness: limited staffing prevented sufficient segregation of duties. Management said it intended to address this by hiring accounting personnel when resources permit.
- No material pending or threatened litigation was reported. The company disclosed no off-balance-sheet arrangements and no specific forward financial guidance beyond the stated financing need. An additional $5,324 loan from the CEO was received in April 2013.
Most important facts for investors to verify
- Confirm that this March 31, 2013 filing is the intended issuer and reporting period, given the mismatch with the request metadata.
- Assess the company’s ability to raise the stated $7.5 million and the timing and terms of any financing, particularly given zero cash and defaulted loans.
- Review the going-concern disclosure, current liabilities, related-party borrowings, and loan maturities or renegotiations.
- Verify the share issuances, returned shares, and settlement accounting underlying the reported share count and $107,939 settlement loss.
- Track preclinical and patent progress, since the company had no marketed product or clinical-stage product and reported very limited R&D expense in the period.
- Determine whether the disclosed material weakness in financial reporting controls has been remediated.